• Founded: 2016
  • Location: South SF, CA
  • Employee range: 11 - 50
  • Clinical stage: RD
  • Therapy area: Neuromuscular diseases
  • Drug types: GEN, MUS, NEU
  • Lead product: Undisclosed
  • Product link:
  • Funding: $8.5M Dec 2018
  • Investors: Data Collective Bio, SK Holdings, Sequoia Capital, Bow Capital

job board

Short description:

Nonviral CRISPR-delivery system

Drug notes:

Contact us to add description:

Long description:

GenEdit is developing safe and efficient gene editing. Delivery remains a major challenge for gene editing therapies and limits the therapies’ performance. To improve delivery, GenEdit has developed a delivery platform called NanoGalaxy, which contains a library of unique non-viral, non-lipid, polymer nanoparticles that can be used as vectors for gene therapies. Polymer backbones are combined with small molecules to create a vast polymer diversity which GenEdit screens. Diversity in charge, size and composition offers a unique array of properties that affect the tissue-targeting specificity and durability. GenEdit is primarily interested in the lung, CNS and immune system for tissue targeting. By targeting these tissues selectively, GenEdit aids in the development of therapeutics for patients with high unmet medical need.


Immulology_Sr. Scientist
South San Francisco, CAOn-site|6 days ago
Molecular Biologist_Sr. Research Associate/Associa...
South San Francisco, CAOn-site|24 days ago
Office & Operations Coordinator (Part-time)
South San Francisco, CAOn-site|48 days ago
Immunology_Sr Research Associate/Associate Scienti...
South San Francisco, CAOn-site|51 days ago

© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy